Primavera Capital Acquisition Corporation
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Primavera Capital Acquisition Corporation operates as a special purpose acquisition company (SPAC) formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations with one or more businesses. It functions as an affiliate of Primavera Capital Group, a global alternative investment management firm managing approximately US$17 billion in assets, with investment strategies including buy-out/control-oriented investments, growth capital, and restructuring investments. The company focuses on leveraging cross-border investment expertise, particularly with deep connectivity in the Asia Pacific region combined with global best practices. Primavera Capital Acquisition Corporation primarily targets global consumer companies with significant presence or growth potential in China. The company completed a major business combination with Lanvin Group Holdings Limited, a global luxury fashion group, through a reverse merger transaction announced in late 2022. This transaction valued Lanvin Group with a pro forma enterprise value of approximately US$1.5 billion and a combined pro forma equity value near US$1.9 billion. Post-combination, the company expanded its strategic footprint in the luxury consumer segment, integrating Lanvin’s portfolio of heritage brands with its investment platform. Strategic alliances include the addition of South Korea’s Handsome Corporation as a strategic investor in the Lanvin Group, further strengthening the company’s market position in Asia. Primavera Capital Acquisition Corporation's core offerings now encompass the luxury fashion and lifestyle sector through Lanvin Group's portfolio, including premium brand management, retail and wholesale distribution channels, e-commerce platforms, and comprehensive supply chain networks focused on craftsmanship and sustainability. With operational locations spanning Asia—Hong Kong, Beijing, Shanghai, Singapore—and Silicon Valley, the company supports a global consumer ecosystem by combining local market expertise with scalable e-commerce and marketing solutions. Primavera continues to pursue organic growth and acquisition-driven expansion in the luxury and lifestyle markets. Founded as a blank check company and listed on the New York Stock Exchange under the ticker PV, Primavera Capital Acquisition Corporation strategically aligns its operations with Primavera Capital Group’s broader alternative investment activities, which include managing USD and RMB funds serving institutional investors, sovereign wealth funds, pension plans, endowments, corporations, and family offices worldwide. The company is headquartered with a significant presence in key financial centers in Asia and the United States. Recent developments reflect Primavera’s ongoing commitment to sustainable and responsible investing practices, integration of advanced marketing and digital commerce strategies, and collaboration with top-tier strategic partners to accelerate growth and facilitate innovations in consumer-driven ecosystems. These changes position Primavera Capital Acquisition Corporation as a pivotal investment and operating vehicle bridging global luxury consumer markets and China’s dynamic economy.
Company News
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
Deciphera Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 INTREPID Study of Sapablursen in Polycythemia Vera
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
Sigenergy Unveils SigenAgent, the First All-Domain AI Agent for the Renewable Energy Industry
Sigenergy Unveils SigenAgent, the First All-Domain AI Agent for the Renewable Energy Industry
Clean Energy & Industrial Demand to Drive Long-Term Silver ETF Growth
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
Westfuller Advisors, LLC Buys 2,132 Shares of T1 Energy Inc (TE)
Stone House Investment Management, LLC Buys 2,500 Shares of T1 Energy Inc (TE)
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
ees Europe: Battery Storage – Powerbanks for the Energy Transition
BESREMi® (Ropeginterferon alfa-2B) Shows Greatest Benefit Among Cytoreductive Therapies in Lowering Symptomatic Burden of Polycythemia Vera (PV): Real-World Analysis Published at ASCO
Ampt Completes Delivery to Edison Power for Solar+Storage Microgrid Project Being Developed by Tocoo, Inc. in Japan
New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May Achieve Greater and Quicker Complete Hematologic and Molecular Responses in Polycythemia Vera
JA Solar and BayWa r.e. Sign Strategic Solar Module Distribution Cooperation Agreement for Asia-Pacific Region
Ampt Completes Repowering Project in Japan Allowing PV System to Meet New Utility Requirements